Author

H. Shimokawa

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Interleukin-6 predicts cardiovascular events beyond standard modifiable risk factors in individuals without atherosclerotic cardiovascular disease

Current risk stratification algorithms capture high-risk individuals with classical risk factors or established atherosclerotic cardiovascular disease (ASCVD). However, a clinically relevant proportion of individuals without threshold levels of standard modifiable risk factors (SMuRF) – namely hypertension, dysli...

F. Kahles, B. Kurt, K. Schneider et al. · European Heart Journal · 0 citations

Open access Oct 2026

Longitudinal high-sensitivity C-reactive protein assessment predicts cardiovascular risk in apparently healthy individuals

High-sensitivity C-reactive protein (hsCRP) is the guideline-recommended biomarker for assessment of residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD). Clinical adoption remains limited, especially in individuals without established ASCVD. This study used longitudinal measurements to ev...

B. Kurt, M. Reugels, K. Schneider et al. · European Heart Journal · 0 citations

Open access Oct 2026

Prognostic impact of high-sensitivity C-reactive protein trajectories and sustained residual inflammation for prediction of cardiovascular outcomes

Traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) fail to fully reflect the residual risk, driven by chronic low-grade inflammation, observed in many. Generally, high-sensitivity C-reactive protein (hsCRP) concentrations remain stable, but some individuals may experience increases. More...

F. Kahles, M. Reugels, K. Schneider et al. · European Heart Journal · 0 citations